Brokerages expect that Neuronetics Inc (NASDAQ:STIM) will report ($0.45) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Neuronetics’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.42). Neuronetics reported earnings per share of ($0.35) in the same quarter last year, which would suggest a negative year-over-year growth rate of 28.6%. The firm is expected to announce its next earnings report on Tuesday, March 3rd.
On average, analysts expect that Neuronetics will report full-year earnings of ($1.63) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.59). For the next year, analysts forecast that the firm will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.75) to ($1.46). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Neuronetics.
Neuronetics (NASDAQ:STIM) last released its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Neuronetics had a negative net margin of 45.35% and a negative return on equity of 44.10%. The firm had revenue of $16.00 million during the quarter, compared to analyst estimates of $16.13 million.
Several equities analysts have recently issued reports on STIM shares. BTIG Research lowered their target price on shares of Neuronetics to $11.00 and set an “average” rating for the company in a report on Wednesday, November 6th. ValuEngine upgraded shares of Neuronetics from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research lowered shares of Neuronetics from a “buy” rating to a “hold” rating in a report on Saturday, November 9th.
In other news, Director Brian E. Farley acquired 19,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average cost of $4.60 per share, for a total transaction of $87,400.00. Following the acquisition, the director now directly owns 136,606 shares in the company, valued at $628,387.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brian E. Farley acquired 11,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $4.27 per share, with a total value of $46,970.00. Following the completion of the acquisition, the director now owns 136,606 shares in the company, valued at $583,307.62. The disclosure for this purchase can be found here. Insiders have bought 67,459 shares of company stock valued at $297,135 over the last quarter. Company insiders own 12.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Novo Holdings A S raised its holdings in Neuronetics by 11.0% in the 2nd quarter. Novo Holdings A S now owns 582,798 shares of the company’s stock worth $7,291,000 after acquiring an additional 57,798 shares during the last quarter. Morgan Stanley grew its position in Neuronetics by 5,765.4% in the 2nd quarter. Morgan Stanley now owns 110,681 shares of the company’s stock worth $1,385,000 after purchasing an additional 108,794 shares during the period. Vanguard Group Inc. grew its position in Neuronetics by 13.9% in the 2nd quarter. Vanguard Group Inc. now owns 489,410 shares of the company’s stock worth $6,123,000 after purchasing an additional 59,853 shares during the period. BlackRock Inc. grew its position in Neuronetics by 6.2% in the 2nd quarter. BlackRock Inc. now owns 978,044 shares of the company’s stock worth $12,235,000 after purchasing an additional 57,297 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Neuronetics by 4.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,506 shares of the company’s stock worth $394,000 after purchasing an additional 1,270 shares during the period. Institutional investors own 80.75% of the company’s stock.
Shares of STIM stock traded down $0.04 during trading hours on Wednesday, hitting $4.50. 154,701 shares of the company’s stock traded hands, compared to its average volume of 110,064. The stock’s fifty day simple moving average is $6.46 and its two-hundred day simple moving average is $9.99. Neuronetics has a 12-month low of $3.96 and a 12-month high of $21.25. The stock has a market cap of $80.49 million, a price-to-earnings ratio of -1.67 and a beta of 0.66. The company has a quick ratio of 4.23, a current ratio of 4.36 and a debt-to-equity ratio of 0.50.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
See Also: Gap Up Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.